Related Experiment Video
Updated: Jan 3, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer
Hongxue Meng1, Xuejie Guo2, Dawei Sun3
1Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
Abstract:
Worldwide, especially in China, lung cancer accounts to a major cause of mortality related to cancer. Treatment decisions mainly depend on oncogenic driver mutations, which offer novel therapeutic targets for anticancer therapy. However, studies of genomic profiling of driver gene mutations in mainland China are rare. Hence, this is an extensive study of these mutations in Non-small-cell lung cancer (NSCLC) Chinese patients. Comparison of driver gene mutations of lung adenocarcinoma with other races showed that the mutational frequencies were similar within the different East Asian populations, while there were differences between East Asian and non-Asian populations. Further, four promising candidates for druggable mutations of epidermal growth factor receptor (EGFR) were revealed that open up avenues to develop and design personal therapeutic approaches for patients harboring mutations. These results will help to develop personalized therapy targeting NSCLC.
Insights
This study analyzed driver gene mutations in Chinese lung cancer patients, revealing similarities in East Asian populations and identifying potential new targets for personalized therapies, particularly for EGFR mutations.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Lung cancer is a leading cause of cancer mortality globally, particularly in China.
- Treatment strategies for lung cancer increasingly rely on identifying oncogenic driver mutations for targeted therapies.
- Genomic profiling studies for driver gene mutations in mainland Chinese Non-small-cell lung cancer (NSCLC) populations are limited.
Purpose of the Study:
- To conduct an extensive genomic profiling study of driver gene mutations in Chinese NSCLC patients.
- To compare the frequencies of driver gene mutations in lung adenocarcinoma between Chinese and other racial groups.
- To identify novel druggable mutations for developing personalized therapeutic approaches.
Main Methods:
- Genomic DNA extraction from NSCLC patient samples.
- Next-generation sequencing (NGS) for comprehensive mutation profiling of key driver genes.
- Comparative analysis of mutation frequencies across different ethnic populations.
Main Results:
- Identified specific mutational frequencies of driver genes in Chinese NSCLC patients.
- Observed similarities in mutation patterns within East Asian populations but differences compared to non-Asian populations.
- Discovered four promising druggable mutations within the epidermal growth factor receptor (EGFR) gene.
Conclusions:
- The study provides crucial insights into the genomic landscape of driver mutations in Chinese NSCLC.
- Findings support the need for race-specific considerations in lung cancer genomic profiling.
- Identified EGFR mutations offer potential for developing targeted personalized therapies for Chinese NSCLC patients.
